Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ilorasertib - AbbVie

Next Previous
Drug Profile

Ilorasertib - AbbVie

Alternative Names: A-968660.0; Abbott-968660; ABT-348

Latest Information Update: 25 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; National Cancer Institute (USA); University of Chicago; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Platelet-derived growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 11 Jul 2023 Discontinued - Phase-II for Solid tumours (Late-stage disease) in USA (PO) (NCT02478320)
  • 11 Jul 2023 M.D. Anderson Cancer Center and AbbVie terminates a phase II trial in Solid tumours (Late-stage disease) in US (PO) due to company's decision to discontinue drug development (NCT02478320)
  • 12 May 2022 M.D. Anderson Cancer Center and AbbVie completes a phase II trial in Solid tumours (Late-stage disease) in US (PO) (NCT02478320)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top